GlaxoSmithKline plc (LON:GSK) had its price target increased by Jefferies Group from GBX 1,900 ($23.16) to GBX 1,950 ($23.77) in a research note released on Thursday morning. Jefferies Group currently has a buy rating on the stock.

Several other research firms have also issued reports on GSK. Deutsche Bank AG reaffirmed a hold rating and issued a GBX 1,870 ($22.79) target price on shares of GlaxoSmithKline plc in a report on Wednesday, October 12th. Beaufort Securities reissued a buy rating on shares of GlaxoSmithKline plc in a report on Tuesday, August 2nd. BNP Paribas reissued a neutral rating on shares of GlaxoSmithKline plc in a report on Friday, July 29th. JPMorgan Chase & Co. reissued a neutral rating on shares of GlaxoSmithKline plc in a report on Thursday, July 28th. Finally, Sanford C. Bernstein set a GBX 1,755 ($21.39) price objective on GlaxoSmithKline plc and gave the company a neutral rating in a report on Thursday, July 28th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have issued a buy rating to the company. The stock has an average rating of Hold and a consensus price target of GBX 1,687.13 ($20.56).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

GlaxoSmithKline plc (LON:GSK) opened at 1667.00 on Thursday. GlaxoSmithKline plc has a 52 week low of GBX 1,277.25 and a 52 week high of GBX 1,745.56. The company’s market cap is GBX 81.03 billion. The stock has a 50 day moving average price of GBX 1,651.49 and a 200 day moving average price of GBX 1,567.94.

The business also recently disclosed a dividend, which was paid on Thursday, October 13th. Stockholders of record on Thursday, August 11th were paid a dividend of GBX 19 ($0.23) per share. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.12%.

In related news, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.63), for a total value of £169,300 ($206,337.60). Also, insider Slaoui,Moncef bought 28 shares of the business’s stock in a transaction that occurred on Friday, August 12th. The stock was acquired at an average cost of GBX 2,208 ($26.91) per share, for a total transaction of £618.24 ($753.49).

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with's FREE daily email newsletter.